290.92 USD
+2.36
0.82%
At close Apr 30, 4:00 PM EDT
After hours
288.00
-2.92
1.00%
1 day
0.82%
5 days
4.47%
1 month
-6.62%
3 months
2.43%
6 months
-7.80%
Year to date
12.20%
1 year
6.20%
5 years
21.61%
10 years
84.23%
 

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 28,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

24% more first-time investments, than exits

New positions opened: 292 | Existing positions closed: 235

1.79% more ownership

Funds ownership: 75.91% [Q3] → 77.7% (+1.79%) [Q4]

9% more call options, than puts

Call options by funds: $1.98B | Put options by funds: $1.82B

0% more funds holding

Funds holding: 2,789 [Q3] → 2,790 (+1) [Q4]

5% less repeat investments, than reductions

Existing positions increased: 1,061 | Existing positions reduced: 1,111

14% less capital invested

Capital invested by funds: $130B [Q3] → $111B (-$18.9B) [Q4]

46% less funds holding in top 10

Funds holding in top 10: 69 [Q3] → 37 (-32) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$294
1%
upside
Avg. target
$318
9%
upside
High target
$330
13%
upside

4 analyst ratings

positive
25%
neutral
50%
negative
25%
UBS
Colin Bristow
25% 1-year accuracy
3 / 12 met price target
10%upside
$319
Neutral
Maintained
14 Apr 2025
Morgan Stanley
Terence Flynn
50% 1-year accuracy
11 / 22 met price target
13%upside
$330
Equal-Weight
Maintained
9 Apr 2025
B of A Securities
Tim Anderson
47% 1-year accuracy
7 / 15 met price target
1%upside
$294
Underperform
Maintained
5 Mar 2025
Piper Sandler
David Amsellem
56% 1-year accuracy
18 / 32 met price target
13%upside
$329
Overweight
Maintained
10 Feb 2025

Financial journalist opinion

Based on 48 articles about AMGN published over the past 30 days

Positive
Zacks Investment Research
9 hours ago
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Positive
Zacks Investment Research
1 day ago
Can Amgen Keep the Beat Streak Alive This Earnings Season?
Volume growth of AMGN's key drugs like Evenity, Repatha and Kyprolis is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Can Amgen Keep the Beat Streak Alive This Earnings Season?
Neutral
PRNewsWire
2 days ago
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets.
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
Positive
Zacks Investment Research
2 days ago
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Positive
Zacks Investment Research
2 days ago
Amgen (AMGN) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Amgen (AMGN) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Positive
The Motley Fool
4 days ago
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Positive
Fox Business
5 days ago
Amgen CEO announces $1 billion in new investments
Amgen chairman and CEO Robert Bradway unpacks the company's investments on 'The Claman Countdown.'
Amgen CEO announces $1 billion in new investments
Positive
Reuters
5 days ago
Amgen to expand Ohio biotech manufacturing plant
Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump administration threats of potential import tariffs.
Amgen to expand Ohio biotech manufacturing plant
Neutral
PRNewsWire
5 days ago
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif. , April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion.
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Negative
Reuters
5 days ago
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
Charts implemented using Lightweight Charts™